Table 3.

Mutation rate by clinical criteria, sex, site, and stage

Clinical criteria
Sex
Tumor site
Duke's stage
Amsterdam I/II (%)No Amsterdam (%)Female (%)Male (%)Left (%)Right (%)A + B (%)C + D (%)
KRAS10/28 (35.7)13/29 (44.8)15/38 (39.5)8/19 (42.1)15/35 (42.9)9/22 (36.4)13/29 (48.3)9/28 (32.1)
BRAF1/28 (3.6)1/29 (3.4)1/38 (2.6)1/19 (5.3)02/22 (9.1)02/28 (7.1)
APC*5/28 (17.9)5/24 (20.8)7/35 (20.0)3/17 (17.6)7/32 (21.9)3/20 (15.0)6/24 (25.0)4/28 (14.3)
MGMT5/25 (20)3/19 (15.8)5/33 (15.1)3/11 (27.3)5/29 (17.2)3/15 (20.0)6/20 (30.0)2/24 (8.3)
  • * APC mutation analysis was not done in 5 out of 57 samples due to shortage of tumoral DNA.

  • Reliable immunohistochemical data regarding MGMT protein expression was obtained in 44 out of 57 tumors.